<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2026-1-6-14</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-6391</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Дифференцировочный статус клеток рака молочной железы, его сопряженность с метастазированием и с продукцией опухолью цитокинов при различных молекулярных подтипах</article-title><trans-title-group xml:lang="en"><trans-title>The differentiation status of breast cancer cells, its association with metastasis and the production of cytokines by the tumor in various molecular subtypes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1390-4426</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Архипов</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Arkhipov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Архипов Сергей Алексеевич – д-р биол. наук, вед. науч. сотрудник, Центральная научно-исследовательская лаборатория; ст. науч. сотрудник</p><p>Россия, 630091, г. Новосибирск, Красный проспект, 52Россия, 630117, г. Новосибирск, ул. Тимакова, 2 </p></bio><bio xml:lang="en"><p>52 Krasny Ave., 630091 Novosibirsk, Russian Federation</p><p>2 Timakova St., 630117 Novosibirsk, Russian Federation </p></bio><email xlink:type="simple">arhipowsergei@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8364-819X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Михайлова</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Mikhaylova</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михайлова Елена Семёновна – науч. сотрудник, Центральная научно-исследовательская лаборатория; науч. сотрудник</p><p>Россия, 630091, г. Новосибирск, Красный проспект, 52Россия, 630117, г. Новосибирск, ул. Тимакова, 2 </p></bio><bio xml:lang="en"><p>52 Krasny Ave., 630091 Novosibirsk, Russian Federation2 Timakova St., 630117 Novosibirsk, Russian Federation </p></bio><email xlink:type="simple">elena.michajlova.58@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-0172-0905</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Архипова</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Arkhipova</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Архипова Валентина Валериевна – мл. науч. сотрудник, Центральная научно-исследовательская лаборатория </p><p>Россия, 630091, г. Новосибирск, Красный проспект, 52</p></bio><bio xml:lang="en"><p>52 Krasny Ave., 630091 Novosibirsk, Russian Federation</p></bio><email xlink:type="simple">valia.arkhipova@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-9279-8395</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дружинина</surname><given-names>Ю. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Druzhinina</surname><given-names>Y. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дружинина Юлия Геннадьевна – ст. науч. сотрудник</p><p>Россия, 630559, Новосибирская область, пгт Кольцово </p></bio><bio xml:lang="en"><p>Koltsovo, 630559 Novosibirsk, Russian Federation </p></bio><email xlink:type="simple">druzhinina@vector-best.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-7802-5486</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковлева</surname><given-names>К. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakovleva</surname><given-names>K. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Яковлева Ксения Игоревна – ст. науч. сотрудник</p><p>Россия, 630559, Новосибирская область, пгт Кольцово</p></bio><bio xml:lang="en"><p>Koltsovo, 630559 Novosibirsk, Russian Federation </p></bio><email xlink:type="simple">yakovlevak@vector-best.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7180-010X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аутеншлюс</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Autenshlyus</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аутеншлюс Александр Исаевич – д-р биол. наук, профессор, зав. Центральной научно-исследовательской лабораторией; гл. науч. сотрудник</p><p>Россия, 630091, г. Новосибирск, Красный проспект, 52Россия, 630117, г. Новосибирск, ул. Тимакова, 2 </p></bio><bio xml:lang="en"><p>52 Krasny Ave., 630091 Novosibirsk, Russian Federation2 Timakova St., 630117 Novosibirsk, Russian Federation </p></bio><email xlink:type="simple">lpciip@211.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Новосибирский государственный медицинский университет (НГМУ);&#13;
Научно-исследовательский институт молекулярной  биологии и биофизики (НИИМББ), Федеральный исследовательский центр фундаментальной и  трансляционной медицины (ФИЦ ФТМ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University;&#13;
Research Institute of Molecular Biology and Biophysics,  Federal Research Center for Fundamental and Translational Medicine (FRC FTM)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Новосибирский государственный медицинский университет (НГМУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>АО «Вектор-Бест»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Vector-Best JSC</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>13</day><month>04</month><year>2026</year></pub-date><volume>25</volume><issue>1</issue><fpage>6</fpage><lpage>14</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Архипов С.А., Михайлова Е.С., Архипова В.В., Дружинина Ю.Г., Яковлева К.И., Аутеншлюс А.И., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Архипов С.А., Михайлова Е.С., Архипова В.В., Дружинина Ю.Г., Яковлева К.И., Аутеншлюс А.И.</copyright-holder><copyright-holder xml:lang="en">Arkhipov S.A., Mikhaylova E.S., Arkhipova V.V., Druzhinina Y.G., Yakovleva K.I., Autenshlyus A.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/6391">https://bulletin.ssmu.ru/jour/article/view/6391</self-uri><abstract><p>Цель. Исследовать взаимосвязь между дифференцировочным статусом опухолевых клеток (далее КО) рака молочной железы (РМЖ) различных молекулярных подтипов, способностью к метастазированию и модуляции в образцах РМЖ продукции различных цитокинов in vitro.Материалы и методы. Исследовали биоптаты РМЖ (инвазивной карциномы молочной железы неспецифического типа) 50 женщин при наличии (Мет+) и отсутствии (Мет-) метастазов в регионарных лимфатических узлах, разделенных на четыре группы по молекулярным подтипам РМЖ: люминальный А (Люм А), люминальный B (Люм B), HER2/neu позитивный (HER2+) и тройной негативный (ТН). С помощью иммуноферментного анализа в супернатанте культивируемых образцов РМЖ определяли спонтанную и стимулированную комплексом митогенов (КМ) продукцию 14 цитокинов (интерлейкин (IL) 2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-1β, IL-1Ra, фактор некроза опухоли альфа, интерферон-гамма (IFNγ), гранулоцитарный колониестимулирующий фактор, гранулоцитарно-макрофагальный колониестимулирующий фактор (GM-CSF), фактор роста эндотелия сосудов и моноцитарный хемоаттрактантный белок-1 (MCP-1)), на основе которой рассчитывали индекс влияния КМ на продукцию цитокинов (ИВКМ). Эффект стимуляции дифференцировки КО in vitro оценивали на основе цитоморфологических критериев по снижению относительного содержания низкодифференцированных клеток (НДКО) в образцах РМЖ.Результаты. Статистически значимое снижение НДКО под воздействием КМ выявлено в группах Мет+ и Мет-. Комплекс митогенов оказывал дифференцировочный эффект при люминальных и HER2-позитивном подтипах, в образцах ТН наблюдалась тенденция к снижению НДКО. Для оценки роли цитокинов в механизме дифференцирующего действия КМ проведен нейросетевой анализ ИВКМ в отношении различных цитокинов. Согласно полученным результатам, при Люм А ведущая роль в проявлении дифференцировочного эффекта была связана с IL-1Ra и IL-6, при Люм B – с MCP-1 и GM-CSF, при HER2+ – с IFNγ и MCP-1, а при ТН – с IL-1β и IL-6.Заключение. Полученные данные свидетельствуют о том, что иммунные механизмы, опосредующие дифференцировочное воздействие КМ на КО РМЖ, могут отличаться при различных молекулярных подтипах РМЖ.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To investigate the relationship between the differentiation status of breast cancer (BC) tumor cells (TC) of various molecular subtypes, the ability to metastasize, and the modulation of various cytokines in BC samples in vitro.Materials and methods. Biopsies from invasive breast carcinoma of a non-specific type in 50 women, classified by the presence (Met+) and absence (Met–) of metastases in regional lymph nodes, were examined and categorized into 4 groups based on their molecular subtypes: luminal A (Lum A), luminal B (Lum B), HER2/neu positive (HER2+), and triple negative (TN). Using enzyme-linked immunosorbent assay, spontaneous and mitogen complex-stimulated (MC) production of 14 cytokines was determined in the supernatant of cultured BC samples (IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-1β, IL-1Ra, TNF-α, IFN-γ, G-CSF, GM-CSF, VEGF, and MCP-1), on the basis of which the index of the MC effect (IMCE) on cytokine production was calculated. The effect of stimulating the differentiation of TC was evaluated on the basis of cytomorphological criteria for reducing the relative content of low-grade cells (LGC) in BC samples.Results. A statistically significant decrease in the relative content of LGC under the influence of MC was detected in the Met+ and Met– groups. MC had a differentiating effect in luminal and HER2-positive subtypes, while in TN breast cancer samples there was only a downward trend in the proportion of LGC. To assess the role of cytokines in the mechanism of the differentiating effect of MC on LGC, a neural network analysis of IMCE in the relationship of various cytokines was carried out. According to the results obtained, in Lum A, the leading role in the manifestation of the differentiation effect was associated with IL-1Ra and IL-6; in Lum B, with MCP-1 and GM-CSF; in HER2+, with IFN-γ and MCP-1, and in TN – with IL-1β and IL-6.Conclusion. The data obtained indicate that the immune mechanisms mediating the differentiating MC effect on BC may vary in different molecular subtypes of BC.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>цитокины</kwd><kwd>молекулярные подтипы</kwd><kwd>клеточная дифференцировка</kwd></kwd-group><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>cytokines</kwd><kwd>molecular subtypes</kwd><kwd>cellular differentiation</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Финансирование тем государственных заданий: № госрегистрации 115060410035, 125031203556-7.</funding-statement><funding-statement xml:lang="en">Financing of government assignment topics: state registration number 115060410035, state registration number 125031203556-7.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Терпинская Т.И. Механизмы лекарственной резистентности опухолей: краткий обзор современных данных. Новости медико-биологических наук. 2022;22(2):160–174.</mixed-citation><mixed-citation xml:lang="en">Терпинская Т.И. Механизмы лекарственной резистентности опухолей: краткий обзор современных данных. Новости медико-биологических наук. 2022;22(2):160–174.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Yan M., Liu Q. Differentiation therapy: a promising strategy for cancer treatment. Chin. J. Cancer. 2016;35(3). DOI: 10.1186/s40880-015-0059-x.</mixed-citation><mixed-citation xml:lang="en">Yan M., Liu Q. Differentiation therapy: a promising strategy for cancer treatment. Chin. J. Cancer. 2016;35(3). DOI: 10.1186/s40880-015-0059-x.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bar-Hai N., Ishay-Ronen D. Engaging plasticity: differentiation therapy in solid tumors. Front. Pharmacol. 2022;13:944773. DOI: 10.3389/fphar.2022.944773.</mixed-citation><mixed-citation xml:lang="en">Bar-Hai N., Ishay-Ronen D. Engaging plasticity: differentiation therapy in solid tumors. Front. Pharmacol. 2022;13:944773. DOI: 10.3389/fphar.2022.944773.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Madan V., Koeffler H.P. Differentiation therapy of myeloid leukemia: four decades of development. Haematologica. 2021;106(1). DOI: 10.3324/haematol.2020.262121.</mixed-citation><mixed-citation xml:lang="en">Madan V., Koeffler H.P. Differentiation therapy of myeloid leukemia: four decades of development. Haematologica. 2021;106(1). DOI: 10.3324/haematol.2020.262121.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Turner K.M., Yeo S.K., Holm T.M., Shaughnessy E., Guan J.L. Heterogeneity within molecular subtypes of breast cancer. Am. J. Physiol. Cell Physiol. 2021;321(2):343–C354. DOI: 10.1152/ajpcell.00109.2021.</mixed-citation><mixed-citation xml:lang="en">Turner K.M., Yeo S.K., Holm T.M., Shaughnessy E., Guan J.L. Heterogeneity within molecular subtypes of breast cancer. Am. J. Physiol. Cell Physiol. 2021;321(2):343–C354. DOI: 10.1152/ajpcell.00109.2021.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Carvalho E., Canberk S., Schmitt F., Vale N. Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies. Cancers. 2025;17(7):1102. DOI: 10.3390/cancers17071102.</mixed-citation><mixed-citation xml:lang="en">Carvalho E., Canberk S., Schmitt F., Vale N. Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies. Cancers. 2025;17(7):1102. DOI: 10.3390/cancers17071102.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Li X., Zhou J., Xiao M., Zhao L., Zhao Y., Wang S. et al. Uncovering the subtype-specific molecular characteristics of breast cancer by multiomics analysis of prognosis-associated genes, driver genes, signaling pathways, and immune activity. Front. Cell Dev. Biol. 2021;9:689028. DOI: 10.3389/fcell.2021.689028.</mixed-citation><mixed-citation xml:lang="en">Li X., Zhou J., Xiao M., Zhao L., Zhao Y., Wang S. et al. Uncovering the subtype-specific molecular characteristics of breast cancer by multiomics analysis of prognosis-associated genes, driver genes, signaling pathways, and immune activity. Front. Cell Dev. Biol. 2021;9:689028. DOI: 10.3389/fcell.2021.689028.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Akinsipe T., Mohamedelhassan R., Akinpelu A., Pondugula S.R., Mistriotis P., Avila L.A. et al. Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics. Front. Immunol. 2024;15:1302587. DOI: 10.3389/fimmu.2024.1302587.</mixed-citation><mixed-citation xml:lang="en">Akinsipe T., Mohamedelhassan R., Akinpelu A., Pondugula S.R., Mistriotis P., Avila L.A. et al. Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics. Front. Immunol. 2024;15:1302587. DOI: 10.3389/fimmu.2024.1302587.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J., Wei Y., Yang W., Huang Q., Chen Y., Zeng K. et al. IL-6: The link between inflammation, immunity and breast cancer. Front. Oncol. 2022;12:903800. DOI: 10.3389/fonc.2022.903800.</mixed-citation><mixed-citation xml:lang="en">Chen J., Wei Y., Yang W., Huang Q., Chen Y., Zeng K. et al. IL-6: The link between inflammation, immunity and breast cancer. Front. Oncol. 2022;12:903800. DOI: 10.3389/fonc.2022.903800.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jorgovanovic D., Song M., Wang L., Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomarker Research. 2020;8:49. DOI: 10.1186/s40364-020-00228-x.</mixed-citation><mixed-citation xml:lang="en">Jorgovanovic D., Song M., Wang L., Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomarker Research. 2020;8:49. DOI: 10.1186/s40364-020-00228-x.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Патент РФ на изобретение № 2697199 / 13.08.2019. Бюл. № 23. Аутеншлюс А.И., Архипов С.А., Михайлова Е.С., Маринкин И.О., Вараксин Н.А. Композиция для повышения содержания высокодифференцированных клеток в аденокарциноме молочной железы. https://patents.google.com/patent/RU2697199C1/ru. Ссылка активна на 03.05.2025.</mixed-citation><mixed-citation xml:lang="en">Патент РФ на изобретение № 2697199 / 13.08.2019. Бюл. № 23. Аутеншлюс А.И., Архипов С.А., Михайлова Е.С., Маринкин И.О., Вараксин Н.А. Композиция для повышения содержания высокодифференцированных клеток в аденокарциноме молочной железы. https://patents.google.com/patent/RU2697199C1/ru. Ссылка активна на 03.05.2025.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Nascimento R.G., Otoni K.M. Histological and molecular classification of breast cancer: what do we know? Mastology. 2020;30:e20200024. DOI: 10.29289/25945394202020200024.</mixed-citation><mixed-citation xml:lang="en">Nascimento R.G., Otoni K.M. Histological and molecular classification of breast cancer: what do we know? Mastology. 2020;30:e20200024. DOI: 10.29289/25945394202020200024.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhen H., Yang L., Li L., Yu J., Zhao L., Li Y. et al. Correlation analysis between molecular subtypes and Nottingham Prognostic Index in breast cancer. Oncotarget. 2017;8(43):74096–74105. DOI: 10.18632/oncotarget.18242.</mixed-citation><mixed-citation xml:lang="en">Zhen H., Yang L., Li L., Yu J., Zhao L., Li Y. et al. Correlation analysis between molecular subtypes and Nottingham Prognostic Index in breast cancer. Oncotarget. 2017;8(43):74096–74105. DOI: 10.18632/oncotarget.18242.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ali S., Hamam D., Liu X., Lebrun J.J. Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer. Front. Endocrinol. 2022;13:993570. DOI: 10.3389/fendo.2022.993570.</mixed-citation><mixed-citation xml:lang="en">Ali S., Hamam D., Liu X., Lebrun J.J. Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer. Front. Endocrinol. 2022;13:993570. DOI: 10.3389/fendo.2022.993570.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rakha E.A., Reis-Filho J.S., Baehner F., Dabbs D.J., Decker T., Eusebi V. et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207. DOI: 10.1186/bcr2607.</mixed-citation><mixed-citation xml:lang="en">Rakha E.A., Reis-Filho J.S., Baehner F., Dabbs D.J., Decker T., Eusebi V. et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207. DOI: 10.1186/bcr2607.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Asleh K., Riaz N., Nielsen T.O. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J. Exp. Clin. Cancer Res. 2022;41:265. DOI: 10.1186/s13046-022-02473-z.</mixed-citation><mixed-citation xml:lang="en">Asleh K., Riaz N., Nielsen T.O. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J. Exp. Clin. Cancer Res. 2022;41:265. DOI: 10.1186/s13046-022-02473-z.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tan C., Hu W., He Y., Zhang Y., Zhang G., Xu Y. et al. Cytokine-mediated therapeutic resistance in breast cancer. Cytokine. 2018;108:151–159. DOI: 10.1016/j.cyto.2018.03.020.</mixed-citation><mixed-citation xml:lang="en">Tan C., Hu W., He Y., Zhang Y., Zhang G., Xu Y. et al. Cytokine-mediated therapeutic resistance in breast cancer. Cytokine. 2018;108:151–159. DOI: 10.1016/j.cyto.2018.03.020.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Baker K.J., Houston A., Brint E. IL-1 family members in cancer, two sides to every story. Front. Immunol. 2019;10:1197. DOI: 10.3389/fimmu.2019.01197.</mixed-citation><mixed-citation xml:lang="en">Baker K.J., Houston A., Brint E. IL-1 family members in cancer, two sides to every story. Front. Immunol. 2019;10:1197. DOI: 10.3389/fimmu.2019.01197.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Tunon I., Ricote M., Ruiz A., Fraile B., Paniagua R., Royuela M. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer. 2007;7:158. DOI: 10.1186/1471-2407-7-158.</mixed-citation><mixed-citation xml:lang="en">Garcia-Tunon I., Ricote M., Ruiz A., Fraile B., Paniagua R., Royuela M. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer. 2007;7:158. DOI: 10.1186/1471-2407-7-158.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cruceriu D., Baldasici O., Balacescu O., Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol. 2020;43:1–18. DOI: 10.1007/s13402-019-00489-1.</mixed-citation><mixed-citation xml:lang="en">Cruceriu D., Baldasici O., Balacescu O., Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol. 2020;43:1–18. DOI: 10.1007/s13402-019-00489-1.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S., Anshita D., Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol. 2021;101:107598. DOI: 10.1016/j.intimp.2021.107598.</mixed-citation><mixed-citation xml:lang="en">Singh S., Anshita D., Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol. 2021;101:107598. DOI: 10.1016/j.intimp.2021.107598.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Long X., Ye Y., Zhang L., Liu P., Yu W., Wei F. et al. IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways. Int. J. Oncol. 2016;48(1):5–12. DOI: 10.3892/ijo.2015.3234.</mixed-citation><mixed-citation xml:lang="en">Long X., Ye Y., Zhang L., Liu P., Yu W., Wei F. et al. IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways. Int. J. Oncol. 2016;48(1):5–12. DOI: 10.3892/ijo.2015.3234.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cirella A., Olivera I., Luri-Rey C., Bolaños E., Berraondo P., Melero I. Interleukin-18 in cancer immunology and immunotherapy. Expert Opin. Ther. Targets. 2023;27(11):1035–1042. DOI: 10.1080/14728222.2023.2287574.</mixed-citation><mixed-citation xml:lang="en">Cirella A., Olivera I., Luri-Rey C., Bolaños E., Berraondo P., Melero I. Interleukin-18 in cancer immunology and immunotherapy. Expert Opin. Ther. Targets. 2023;27(11):1035–1042. DOI: 10.1080/14728222.2023.2287574.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Akinsipe T., Mohamedelhassan R., Akinpelu A., Pondugula S.R., Mistriotis P., Avila L.A. et al. Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics. Front. Immunol. 2024;15:1302587. DOI: 10.3389/fimmu.2024.1302587.</mixed-citation><mixed-citation xml:lang="en">Akinsipe T., Mohamedelhassan R., Akinpelu A., Pondugula S.R., Mistriotis P., Avila L.A. et al. Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics. Front. Immunol. 2024;15:1302587. DOI: 10.3389/fimmu.2024.1302587.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
